1042 related articles for article (PubMed ID: 25987009)
1. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
3. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
[TBL] [Abstract][Full Text] [Related]
4. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Kudo M
J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
[TBL] [Abstract][Full Text] [Related]
5. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.
Mak LY; Cruz-Ramón V; Chinchilla-López P; Torres HA; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Bailey HH; Méndez-Sánchez N; Yuen MF; Hwang JP
Am Soc Clin Oncol Educ Book; 2018 May; 38():262-279. PubMed ID: 30231359
[TBL] [Abstract][Full Text] [Related]
6. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.
Song PP; Xia JF; Inagaki Y; Hasegawa K; Sakamoto Y; Kokudo N; Tang W
World J Gastroenterol; 2016 Jan; 22(1):262-74. PubMed ID: 26755875
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of hepatocellular carcinoma.
Omata M; Yoshida H
Liver Transpl; 2004 Feb; 10(2 Suppl 1):S111-4. PubMed ID: 14762850
[TBL] [Abstract][Full Text] [Related]
8. [The diagnostic approach to hepatocellular carcinoma].
Schacherer D; Schoelmerich J; Zuber-Jerger I
Z Gastroenterol; 2007 Oct; 45(10):1067-74. PubMed ID: 17924305
[TBL] [Abstract][Full Text] [Related]
9. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma.
Okuda K
J Hepatol; 2000; 32(1 Suppl):225-37. PubMed ID: 10728807
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellualar carcinoma serum markers.
Bertino G; Ardiri A; Malaguarnera M; Malaguarnera G; Bertino N; Calvagno GS
Semin Oncol; 2012 Aug; 39(4):410-33. PubMed ID: 22846859
[TBL] [Abstract][Full Text] [Related]
12. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma: therapy and prevention.
Blum HE
World J Gastroenterol; 2005 Dec; 11(47):7391-400. PubMed ID: 16437707
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma tumor board: making sense of the technologies.
Abou-Alfa GK; Marrero J; Renz J; Lencioni R
Am Soc Clin Oncol Educ Book; 2015; ():e213-20. PubMed ID: 25993176
[TBL] [Abstract][Full Text] [Related]
17. Postoperative therapy options for hepatocellular carcinoma.
Zhong JH; Ma L; Li LQ
Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
[TBL] [Abstract][Full Text] [Related]
18. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
Schott E; Bergk A; Berg T
Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
[TBL] [Abstract][Full Text] [Related]
19. Serum markers of hepatocellular carcinoma.
Spangenberg HC; Thimme R; Blum HE
Semin Liver Dis; 2006 Nov; 26(4):385-90. PubMed ID: 17051452
[TBL] [Abstract][Full Text] [Related]
20. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.
Yoo SH; Choi JY; Jang JW; Bae SH; Yoon SK; Kim DG; Yoo YK; Rha SE; Lee YJ; Jung ES
Ann Surg Oncol; 2013 Sep; 20(9):2893-900. PubMed ID: 23649931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
